Company research
Turn Therapeutics Inc.
CIK 2023016Updated Nov 11, 2026
SecurityTTRX · NASDAQ · equity
Name history
Global Health Solutions, Inc · through Sep 30, 2025
TTRX price & chart
Loading TradingView…
NASDAQ:TTRX on TradingView ↗About the company
We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events. Our proprietary platform has been validated across multiple FDA-cleared medical devices.
In the news
No coverage from other publishers is available.
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
S-3 filing
S-3 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
ARS filing
DEF 14A filing
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| AssetsUSD | 4,297,630Source | — | 16,960,719Source | — | 18,644,136Source | — | 12,162,241Source | 2,048,889Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 904,885Source | — | 911,219Source | — | 919,947Source | — | 922,171Source | 821,931Source |
| Current assets: | ||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 513,695Source | 498,286Source | 9,948,952Source | — | 11,009,553Source | — | 4,027,862Source | 498,286Source |
| Assets, CurrentUSD | 3,294,740Source | — | 10,428,198Source | — | 11,452,842Source | — | 5,196,444Source | 1,097,924Source |
| Prepaid Expense and Other Assets, CurrentUSD | 188,583Source | — | 139,688Source | — | 235,171Source | — | 120,300Source | 225,325Source |
| Operating Lease, Right-of-Use AssetUSD | 89,423Source | — | 56,275Source | — | 67,573Source | — | 78,620Source | 120,452Source |
| LIABILITIES AND EQUITY | ||||||||
| LiabilitiesUSD | 3,793,611Source | — | 16,273,831Source | — | 12,526,588Source | — | 7,475,518Source | 2,226,321Source |
| Stockholders’ equity: | ||||||||
| Common Stock, Value, IssuedUSD | 2,802Source | — | 2,977Source | — | 2,977Source | — | 2,943Source | 2,684Source |
| Retained Earnings (Accumulated Deficit)USD | -22,669,163Source | — | -29,210,958Source | — | -23,361,065Source | — | -22,390,093Source | -19,196,013Source |
| Stockholders' Equity Attributable to ParentUSD | 504,019Source | -414,299Source | 686,888Source | 1,774,496Source | 6,117,548Source | 818,710Source | 4,686,723Source | -177,432Source |
| Additional Paid in Capital, Common StockUSD | 23,223,079Source | — | 29,894,869Source | — | 29,475,636Source | — | 28,143,873Source | 19,015,897Source |
| Liabilities and EquityUSD | 4,297,630Source | — | 16,960,719Source | — | 18,644,136Source | — | 12,162,241Source | 2,048,889Source |
| Current liabilities: | ||||||||
| Liabilities, CurrentUSD | 2,309,254Source | — | 8,764,111Source | — | 5,130,522Source | — | 6,003,424Source | 707,932Source |
| Operating Lease, Liability, CurrentUSD | 44,829Source | — | 49,329Source | — | 47,795Source | — | 46,295Source | 40,660Source |
| Operating Lease, Liability, NoncurrentUSD | 46,344Source | — | 8,713Source | — | 21,539Source | — | 34,081Source | 80,376Source |
| Long-term Debt, Excluding Current Maturities | — | — | —Source | — | —Source | — | — | — |
| Long-term Debt, Excluding Current Maturities | — | — | —Source | — | —Source | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 280,830Source | 76,597Source | 419,245Source | 352,833Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -1,632,807Source | -298,058Source | -2,562,901Source | -1,361,305Source |
| Cash flows from investing activities: | ||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -12,227Source | — | -152,986Source | -99,475Source |
| Cash flows from financing activities: | ||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 7,786,561Source | 998,092Source | 6,919,432Source | 1,152,382Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 3,106,156Source | 788,780Source | 10,288,510Source | 3,189,943Source | 11,217,671Source | 1,572,633Source | 5,076,144Source | 872,599Source |
| Additional Financial Items | ||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | 155,830Source | 76,580Source | 320,000Source | 350,000Source |
| Amortization of Deferred ChargesUSD | — | — | — | — | — | — | 500,000Source | — | 500,000Source | — |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 53,000Source | 47,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | — | -3,341,568Source | — | 697,561Source | — | 2,574,971Source | — |
| General and Administrative ExpenseUSD | — | — | 1,754,856Source | 519,710Source | 1,152,996Source | 1,303,846Source | 1,136,709Source | 375,738Source | 5,593,078Source | 1,551,168Source |
| Investment Income, InterestUSD | — | — | 5,111Source | 6,550Source | — | — | 49,679Source | 5,165Source | 29,583Source | 28,709Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,904,184Source | -666,442Source | -5,849,734Source | -1,240,415Source | -970,972Source | -328,547Source | -3,194,080Source | -1,768,415Source |
| Nonoperating Income (Expense)USD | — | — | 9,371Source | 6,550Source | -4,221,674Source | 126,109Source | 275,171Source | 56,450Source | 2,664,568Source | 28,709Source |
| Operating ExpensesUSD | — | — | 1,913,555Source | 672,992Source | 1,628,060Source | 1,366,524Source | 1,246,143Source | 384,997Source | 5,858,648Source | 1,797,124Source |
| Other Nonoperating Income (Expense)USD | — | — | 4,260Source | — | — | 120,975Source | 5,578Source | 51,285Source | 176,520Source | — |
| Proceeds from Contributed CapitalUSD | — | — | — | — | — | — | — | — | 4,070,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 998,092Source | 6,919,432Source | 1,152,382Source |
| Amortization | — | — | — | — | — | — | —Source | —Source | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -1,913,555Source | -672,992Source | -1,628,060Source | -1,366,524Source | -1,246,143Source | -384,997Source | -5,858,648Source | -1,797,124Source |
| Other Nonoperating Income (Expense)USD | — | — | 4,260Source | — | — | 120,975Source | 5,578Source | 51,285Source | 176,520Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,904,184Source | -666,442Source | -5,849,734Source | -1,240,415Source | -970,972Source | -328,547Source | -3,194,080Source | -1,768,415Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.07Source | -0.03Source | -0.2Source | -0.05Source | -0.03Source | -0.01Source | -0.12Source | -0.07Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.07Source | -0.03Source | -0.2Source | -0.05Source | -0.03Source | -0.01Source | -0.12Source | -0.07Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 27,975,207Source | 26,645,835Source | 29,788,040Source | 27,494,483Source | 29,476,002Source | 26,956,217Source | 27,716,045Source | 26,643,432Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 27,975,207Source | 26,645,835Source | 29,788,040Source | 27,494,483Source | 29,476,002Source | 26,956,217Source | 27,716,045Source | 26,643,432Source |
| Additional Financial Items | ||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 53,000Source | 47,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | — | 52,746Source | 47,483Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | — | -3,341,568Source | — | 697,561Source | — | 2,574,971Source | — |
| General and Administrative ExpenseUSD | — | — | 1,754,856Source | 519,710Source | 1,152,996Source | 1,303,846Source | 1,136,709Source | 375,738Source | 5,593,078Source | 1,551,168Source |
| Investment Income, InterestUSD | — | — | 5,111Source | 6,550Source | — | — | 49,679Source | 5,165Source | 29,583Source | 28,709Source |
| Nonoperating Income (Expense)USD | — | — | 9,371Source | 6,550Source | -4,221,674Source | 126,109Source | 275,171Source | 56,450Source | 2,664,568Source | 28,709Source |
| Operating ExpensesUSD | — | — | 1,913,555Source | 672,992Source | 1,628,060Source | 1,366,524Source | 1,246,143Source | 384,997Source | 5,858,648Source | 1,797,124Source |
| Other ExpensesUSD | — | — | 202,360Source | 359,290Source | 735,222Source | 197,155Source | 546,909Source | 192,943Source | 1,340,138Source | 866,984Source |
| Research and Development ExpenseUSD | — | — | 158,699Source | 153,282Source | 475,064Source | 62,678Source | 109,434Source | 9,259Source | 265,570Source | 245,956Source |
| Interest Income (Expense), Nonoperating, Net | — | — | — | — | —Source | —Source | — | — | — | — |
Offerings
Registration 333-299914
Registration 333-299915
Registration 333-290800
Registration 333-289972
- Deal price
- 11.65
- Offering price
- $11.65
- Ticker
- TTRX
Filing attachments
ea031158701ex99-1.htm · 8-K · 2026-11-10
Exhibit 99.1 November 2026 Corporate Presentation Forward - Looking Statements & Safe Harbor Except for historical information set forth herein, the matters set forth in this presentation contain forward - looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward - looking statements may be identified by words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates,” “pre…
Read attachment ↗ea030998001ex4-5.htm · S-3 · 2026-11-09
Exhibit 4.5 Turn Therapeutics Inc. INDENTURE Dated as of __________, 20__ as Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. …
Read attachment ↗ea031139901ex99-1.htm · 8-K · 2026-11-09
Exhibit 99.1 Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results Completed GX-03 Stage 1/Phase 2a Trial: 59.3% of GX-03 Patients Achieved Clear or Almost Clear Skin After Four Weeks, Compared with 30.4% Receiving Vehicle Larger Phase 2b Atopic Dermatitis Trial Continues, Informed by Findings from Completed Stage 1/Phase 2a Building on GX-03 Momentum, Turn Therapeutics Accelerates Hidradenitis Suppurativa Trial with Enrollment Now Expected to Begin in…
Read attachment ↗ea030791101ex99-1.htm · 8-K · 2026-10-07
Exhibit 99.1 Corporate Presentation October 2026 2 Forward-Looking Statements & Safe Harbor Except for historical information set forth herein, the matters set forth in this presentation contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts…
Read attachment ↗ea030503701ex99-1.htm · 8-K · 2026-09-10
EX-99.1 2 ea030503701ex99-1.htm PRESS RELEASE, DATED SEPTEMBER 10, 2026 Exhibit 99.1 Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum Westlake Village, Calif. - September 10, 2026 - Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and Stephen M. Hahn, M.D., Executive Clinical and Regulatory L…
Read attachment ↗ea030480601ex99-1.htm · 8-K · 2026-09-09
EX-99.1 2 ea030480601ex99-1.htm PRESS RELEASE, DATED SEPTEMBER 9, 2026 Exhibit 99.1 Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer Brings internationally recognized expertise in immunology, cytokine biology, host-microbe interactions and public health Westlake Village, Calif. - September 9, 2026 - Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory a…
Read attachment ↗